Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q2 2019 Earnings Presentation
24 slides from Quanterix's earnings presentation, Aug 6, 2019
Slide 1: Earnings Call Q2 2019
Earnings Call Q2 2019 August 6, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts. We may not actuall
Slide 3: Today's Agenda
Today’s Agenda I. Strategic and Financial Progress – Kevin Hrusovsky – Chairman, CEO i. Company Direction & Q2 Highlights ii. Progress against 2019 Goals & Priorities iii. Transforming Medicine: Neurology Momentum Update II. Financial Report – Amol Chaubal – CFO III. Summary of QTRX Opportunity - Ke
Slide 4: Q2 and 1H 2019 Highlights
Disruptive Market, Technology and Growth Total Quanterix Revenue Growth Q2 and 1H 2019 Highlights Q1 Q2 2H % Reported Growth +65% % Growth excl. Collaboration Revenue +63% • Q2 Revenue $13.5M, 57% growth; 60% growth 1H 37.6 • Q2 GM 51.2% versus 46.0% last yr; 580 bps increase 1H • Added CFO, General
Slide 5: Q2 2019 Growth Led by Consumables and Services
Q2 2019 Growth Led by Consumables and Services Growth $m Revenue Q2 2018 Q2 2019 Mix% Q2 2019: % 1.8 Instruments 2.7 53% 20% • 57% Overall Revenue Growth 77% 45% 3.4 • Total Gross Margin 51.2%, +520 bps Consumables 6.1 Lab. & 3.2 50% 35% Other Services 4.8 Growth $m Revenue 1H 2018 1H 2019 Mix% 1H 2
Slide 6: Transforming Medicine with Digital Biomarkers
Transforming Medicine with Digital Biomarkers Today : Invasive & Late Tomorrow : Non-Invasive & Early Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 6
Slide 7: Simoa Sees Health to Disease Continuum
Simoa Sees Health to Disease Continuum Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 7
Slide 8: Strategic Direction Remains Unchanged
Strategic Direction Remains Unchanged Capture major market opportunity through our disruptive technology Onco LSR Prds and PS Neuro LSR Prds and PS ~$760MM ~$350MM Neuro ~$36B Disruption Diagnostics Bridge ~$5B ~$1.1B ~$350MM Neuro LSR Prds ~$90MM Clinical Diagnostics Neuro LSR Prds Neuro PS Onco PS
Slide 9: 1H 2019 Growth Stratification
1H 2019 Growth Stratification 2% 12% 1% 41% Geography Customer 45% Diseases 52% 54% 34% 59% Growth Growth Growth 97% NA +77% Pharma/Biotech CRO +37% Neurology +83% Europe +86% Academia Oncology +135% +86% Asia +116% Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 9
Slide 10: Scientific Research is Driving Brand Awareness, Performance and Utilization
Scientific Research is Driving Brand Awareness, Performance and Utilization PUBLICATIONS* MARKERS* ACCELERATOR INSTRUMENTS CONSUMABLES $m Revenue # of units: bars # of units: bars Other Number of Drug Trial Projects Instument Revenue Growth vs. PYR Consumables Revenue Growth vs. PYR 567 124% Oncolog
Slide 11: Quanterix Product Offerings
Quanterix Product Offerings Instruments Assay kits Services HD-X SR-X SP-X Plate Bead Accelerator Floor-standing integrated Benchtop semi- Simoa planar assay 300+ assays Contract research & testing automated assay prep Assay prep and detection Benchtop semi- Homebrew kits Custom assay development &
Slide 12: Competitive Landscape
Competitive Landscape Bead-Based Planar SP-X Bead-based Erenna Electrochemi- Technology ELLA Simoa Simoa Immunoassay Immunoassay luminescence Sensitivity Dynamic Range Automation & Ease of Use Precision Multiplexing Menu Cost Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 12
Slide 13: Objectives 2019
Objectives 2019 Large strides in Q2 towards securing our 2019 objectives Neurology <10% Oncology Strategy Financials Technology Penetrated 3x Neuro Dx via Biopharma LT Growth: 40% 100x incremental High double digit growth LDT/IVD partnerships sensitivity by YE 2021 Launch penetration in with high ut
Slide 14: We are Addressing a Significant Unmet Need in Drug Development
We are Addressing a Significant Unmet Need in Drug Development FDA Announces Office of Drug Evaluation Science - ODES DRUG PERFORMANCE PROBABILITY OF DRUG APPROVAL VALIDATION OF SIMOA IMPACT TOXICITY 300% Simoa’S at CROs Trials at Adverse drug events are a substantial 38 32 cause of Death in USA inc
Slide 15: Unmet Need
Unmet Need Development of neurological disease diagnostics has been slow due to disease complexity 1 FDA issuing guidance to enable use of biomarkers in drug trials for early stage disease cohorts Neuro health has become Biopharma industry national Health Priority due discouraged by lack of 2 to vet
Slide 16: Blue Chip Customers
Blue Chip Customers 2019 2018 2017 2016 2015 2014 Research Institutions Biopharma Other Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 16
Slide 17: Strategic Roadmap
Strategic Roadmap Moving Biomarkers from Analytical Validity to Clinical Validity HIGH Analytical Validity Traditional Clinical Validity Late Detection via biopsy and Technology Troponin lumbar puncture PSA ? Biomarker ? Abundance Nf-L ? Early Detection in blood, saliva & urine $ Tau $ ABeta ? ? $ ?
Slide 18: Nf-L Rapidly Expanding as Best In Class Neuro Biomarker
Nf-L Rapidly Expanding as Best In Class Neuro Biomarker RESEARCH PUBLICATIONS ON Nf-L Simoa NfL 45 Meeting Abstracts & Presentations 40 160 35 46 active 30 140 25 clinical trials 20 40 120 PubMed Citations 15 using Nf-L 10 21 100 5 10 0 80 1 AAN 2 ECTRIMS 3 AAN Spring 2018 Fall 2018 Spring 2019 60 5
Slide 19: Uman Nf-L Antibody is unparalleled
Uman Nf-L Antibody is unparalleled Publications (CSF & Blood) Not based on Based on Uman Nf-L Uman Nf-L 23% 112 77% 382 Based on Uman Nf-L 77% 100% 382 172 100% Publications on Blood 172 Based on Uman Nf-L Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 19
Slide 20: Emerging Clinical Biomarker: Neurofilament Light (NfL)
Emerging Clinical Biomarker: Neurofilament Light (NfL) NFL PUBLICATIONS WW DISEASE INCIDENCE (MILLIONS) 25 2015 Our Focus 60 2016 20 50 2017 40 2018 15 30 20 10 10 5 0 MS ALS FTD Parkinsons TBI Alzheimer's Epilepsy 0 Parkinsons FTD ALS Alzheimers TBI MS STUDIES CONFIRM NFL CLINICAL UTILITY: MULTIPLE
Slide 21: Digital Biomarkers Disruption Paradigm
Digital Biomarkers Disruption Paradigm Alzheimer’s Disease Opportunity TODAY Alzheimer’s disease not Imaging expensive and often Therapies for later stage diagnosed until symptoms not covered disease have limited effectiveness TOMORROW Detect or screen in Follow on Image or Therapy delivered sooner
Slide 22: Pattern of AD Drug Failure – Is there Hope?
Pattern of AD Drug Failure – Is there Hope? Roche, Biogen, Amgen, Novartis halting trials early Jan 2019 Can early detection enable AD drug rescue? March 2019 July 2019 Quanterix Earnings Call | Q2 2019 | August 6, 2019 | 22
Slide 23: Q2 2019 & 1H 2019 Financials
Q2 2019 & 1H 2019 Financials Q2 Q2 1H H1 1H H1 $m Revenue in $m 2019 2018 2019 2018 Q2 2018 Q2 2019 +77% 6.1 Product Revenue 8.8 5.2 18.3 9.9 +50% 4.8 Growth vs. PYR 69% 84% +53% 3.4 3.2 Service Revenue 4.8 3.2 7.5 5.7 2.7 1.8 Growth vs. PYR 50% 33% Collaboration Revenue 0.0 0.3 0.0 0.5 Instruments
Slide 24: Poised to Disrupt Healthcare and Create Significant Value
Poised to Disrupt Healthcare and Create Significant Value Differentiator Value Best in 1 Category-defining; Unrivaled Sensitivity / Technology Disrupt Class 2 $3B to New Methodical market penetration strategy to reward investors $40B Answers market 3 DNA – RNA - Protein; Better linked to Disease / H